Homoeriodictyol

Pharmacology & Research

Homoeriodictyol is a yerba santa flavanone — the 3’-O-methyl ether of eriodictyol and a positional isomer of hesperetin — and its honest identity is a flavour ingredient, not a therapeutic. Its real fame (and the reason it is a commercial compound at all) is bitter-masking: the sodium salt suppresses the bitterness of caffeine, quinine, salicin and many pharmaceuticals by antagonising human bitter taste receptors ^{1,2Reference 1Ley JP et al. · 2005Evaluation of bitter-masking flavanones from Herba Santa (Eriodictyon californicum)View study →Reference 2Fletcher JN et al. · 2011In-vitro evaluation of flavonoids from Eriodictyon californicum for antagonist activity against bitter taste receptorsView study →}. It is a genuine yerba-santa leaf constituent (~26–61 mg/g in one cultivated analysis ^{8Reference 82026Chemical composition of Eriodictyon californicum (yerba santa) cultivated in OregonView study →}) and part of the historical chemopreventive fraction ^{7Reference 7Liu YL et al. · 1992Isolation of potential cancer-chemopreventive agents from Eriodictyon californicumView study →}. Its scattered therapeutic signals are thin and preclinical, and one confusion is worth heading off — the potent neuroprotective yerba-santa flavanone is sterubin (a positional isomer, methylated on the A-ring so it keeps the intact catechol B-ring), not homoeriodictyol.

1. Bitter-masking / flavour

The headline and only robustly supported use. In the founding evaluation of bitter-masking flavanones from yerba santa, homoeriodictyol (especially its sodium salt) suppressed the bitterness of caffeine, quinine, salicin and pharmaceuticals in trained sensory panels ^{1Reference 1Ley JP et al. · 2005Evaluation of bitter-masking flavanones from Herba Santa (Eriodictyon californicum)View study →}; the mechanism is antagonism of human bitter taste receptors (hTAS2Rs) ^{2Reference 2Fletcher JN et al. · 2011In-vitro evaluation of flavonoids from Eriodictyon californicum for antagonist activity against bitter taste receptorsView study →}; and it is used as a bitterness suppressor in model beverages ^{3Reference 3Gaudette NJ · 2012Optimising the orosensory properties of model functional beverages (homoeriodictyol-Na bitterness suppression)View study →} and reduced chemotherapy-associated bitterness in a patient mouthwash study ^{9Reference 9Zehentner S et al. · 2026Clinical trialA homoeriodictyol-sodium mouthwash reduces bitterness sensitivity in patients with gynecological cancer receiving chemotherapyView study →}.

Gap: bitter-masking is a perceptual effect — it implies no systemic pharmacology and no disease-modifying benefit ^{1Reference 1Ley JP et al. · 2005Evaluation of bitter-masking flavanones from Herba Santa (Eriodictyon californicum)View study →}.

2. Appetite / gastric bitter-signalling

In two randomised cross-over human interventions, oral homoeriodictyol modulated appetite via bitter-taste signalling ^{4Reference 4Hochkogler CM et al. · 2017RCTAppetite-inducing effects of homoeriodictyol: two randomised cross-over interventionsView study →}, and it has been used as a bitter-receptor antagonist tool to block caffeine-induced gastric acid secretion in parietal cells ^{5Reference 5Liszt KI et al. · 2017Caffeine induces gastric acid secretion via bitter-taste signalling in gastric parietal cells (homoeriodictyol as hTAS2R antagonist)View study →}.

Gap: these are taste-physiology studies (the compound as a bitter-receptor ligand), with small n and sensory-metabolic endpoints, not a therapeutic indication ^{4,5Reference 4Hochkogler CM et al. · 2017RCTAppetite-inducing effects of homoeriodictyol: two randomised cross-over interventionsView study →Reference 5Liszt KI et al. · 2017Caffeine induces gastric acid secretion via bitter-taste signalling in gastric parietal cells (homoeriodictyol as hTAS2R antagonist)View study →}.

3. Anti-inflammatory / neuroprotective

In one mouse study, eriodictyol and homoeriodictyol improved amyloid-β(25–35)-induced memory impairment by inhibiting the NLRP3 inflammasome ^{6Reference 6Guo P et al. · 2022AnimalEriodictyol and homoeriodictyol improve memory impairment in Aβ(25–35)-induced mice by inhibiting the NLRP3 inflammasomeView study →}.

Gap: a single rodent study at high dose, with no replication and no human data — and the potent neuro-activity in yerba santa belongs to sterubin, not homoeriodictyol ^{6Reference 6Guo P et al. · 2022AnimalEriodictyol and homoeriodictyol improve memory impairment in Aβ(25–35)-induced mice by inhibiting the NLRP3 inflammasomeView study →}.

Mechanisms

Target / pathway	Effect	Relevant to
Human bitter taste receptors (hTAS2Rs)	antagonism → suppressed bitter perception (the signature mechanism)	bitter-masking / flavour
Extra-oral hTAS2R signalling (gastric parietal cells)	bitter-receptor antagonist blocks caffeine-triggered gastric acid	gastric/appetite sensory physiology
NLRP3 inflammasome	inhibition (single Aβ mouse study)	anti-inflammatory / neuroprotective (thin)
Radical scavenging (phenolic B-ring)	generic flavanone antioxidant (class-inferred, in vitro)	antioxidant

Only the hTAS2R bitter-receptor antagonism is robustly and specifically established; the rest is single-study or class-inferred.

Pharmacokinetics

Homoeriodictyol is a flavanone aglycone with poor oral bioavailability expected (low solubility, extensive phase-II conjugation and rapid first-pass metabolism, as for its hesperetin/eriodictyol congeners); no dedicated human pharmacokinetic study exists. Crucially, as a flavour ingredient it acts locally in the oral cavity and GI lumen on taste receptors, so systemic absorption is largely irrelevant to its headline use.

Clinical trials

There are no therapeutic-isolate clinical trials. The only human studies are sensory/flavour, not therapeutic: two randomised cross-over appetite/bitter-signalling interventions ^{4Reference 4Hochkogler CM et al. · 2017RCTAppetite-inducing effects of homoeriodictyol: two randomised cross-over interventionsView study →}, a homoeriodictyol-sodium mouthwash reducing chemotherapy-associated bitterness ^{9Reference 9Zehentner S et al. · 2026Clinical trialA homoeriodictyol-sodium mouthwash reduces bitterness sensitivity in patients with gynecological cancer receiving chemotherapyView study →}, and beverage orosensory optimisation ^{3Reference 3Gaudette NJ · 2012Optimising the orosensory properties of model functional beverages (homoeriodictyol-Na bitterness suppression)View study →} — all to be read as flavour/sensory work, never as evidence of therapeutic efficacy.

Completed	Planned	Terminated	Preclinical / sensory
— (no therapeutic isolate trial)	—	—	Flavour/sensory human + thin preclinical

Last checked: July 2026.

Toxicity & Safety

Homoeriodictyol (as its sodium salt) is used as a natural bitter-masking food-flavour ingredient and is regarded as GRAS-adjacent; human sensory studies (mouthwash, beverages, appetite trials) report it as well tolerated at flavour-relevant doses ^{1,3,9Reference 1Ley JP et al. · 2005Evaluation of bitter-masking flavanones from Herba Santa (Eriodictyon californicum)View study →Reference 3Gaudette NJ · 2012Optimising the orosensory properties of model functional beverages (homoeriodictyol-Na bitterness suppression)View study →Reference 9Zehentner S et al. · 2026Clinical trialA homoeriodictyol-sodium mouthwash reduces bitterness sensitivity in patients with gynecological cancer receiving chemotherapyView study →}, with no serious toxicity signal identified and a [low] flag matching the sibling eriodictyol page. Isolated high-dose chronic-toxicity data are not characterised.

Pregnancy & lactation

Dietary/flavour amounts presumably low-concern; avoid isolated supplements. There are no reproductive or developmental safety data for the isolate; incidental flavour-level exposure is presumably low-concern, but isolated or supplemental use is not recommended in pregnancy or lactation on precautionary grounds.

Dosage

There is no established therapeutic dose — there is no therapeutic use to dose for. As a flavour ingredient, the sodium salt is used at low ppm masking concentrations in foods and beverages, determined empirically by sensory panels ^{1,3Reference 1Ley JP et al. · 2005Evaluation of bitter-masking flavanones from Herba Santa (Eriodictyon californicum)View study →Reference 3Gaudette NJ · 2012Optimising the orosensory properties of model functional beverages (homoeriodictyol-Na bitterness suppression)View study →}; no supplement dosing is warranted or supported.

References